42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab® (anti-CD3 X anti-EpCAM)
A. Burges, P. Wimberger, V.A. Gorbounova, H. Sommer, B. Schmalfeldt, J. Pfisterer, M. Ströhlein, M.R. Lichinitser, A.N. Makhson, R. KimmigVolume:
1
Year:
2003
Language:
english
DOI:
10.1016/s1359-6349(03)90076-0
File:
PDF, 164 KB
english, 2003